Joint Accreditation Statement
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2549-L01-P
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Upon completion of this program, participants will be able to:
- Describe recommended uses of immunotherapies for lymphoma as outlined in SITC clinical practice guidelines
- Identify opportunities to incorporate cancer immunotherapy into clinical practice
- Appropriately manage common and uncomplicated toxicities associated with immunotherapy for lymphoma
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
This webinar is supported, in part, by independent medical education grants from
Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.